Both CelGro Nerve and ATI results were due tin 3Q19, so I'd hope J&J ATI trials out before end of October. I suspect its more a case of management preparing the report. Whilst CelGro Nerve trial update on all patients will hopefully move the price up, I suspect J&J ATI trials will be the real mkt mover. J&J would be short-sighted not to form a partnership with poison pill bindings to discourage a takeover of OCC by a rival. Personally if I ran J&J I'd snap them up at the cheap prevailing price. Not the best for long-term holders though.
Upcoming announcements, page-176
-
- There are more pages in this discussion • 19 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OCC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
46.0¢ |
Change
0.005(1.10%) |
Mkt cap ! $96.40M | |||
| Open | High | Low | Value | Volume |
| 45.5¢ | 46.5¢ | 45.5¢ | $87.13K | 189.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 271 | 46.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 46.5¢ | 21507 | 1 |
View Market Depth
| Last trade - 15.40pm 04/10/2024 (20 minute delay) ? |
| OCC (ASX) Chart |